● 睿远公益基金会理事长 睿远基金党支部书记 潘鑫军 公募基金行业步入高质量发展阶段。为了深入贯彻落实《国务院关于加强监管防范风险推动资本市场高 质量发展的若干意见》，中国证监会5月发布《推动公募基金高质量发展行动方案》，为公募基金行业 高质量发展指明了方向。 一家企业、一个行业，必须为客户、为社会作出应有的贡献，在此过程中获得一定收益，这样的商业模 式才能持续，公募基金也是如此。 公募基金行业将在《行动方案》及系列配套政策的指引下逐步重塑行业生态，为投资者、为社会创造长 期价值，这也为公募基金行业长期稳健发展奠定坚实的基础。 坚持以投资者为本 引领行业发展 经过20多年的发展，公募基金行业在服务实体经济与国家战略、促进资本市场改革发展稳定、满足居民 财富管理需求等方面发挥了积极作用，但也存在功能发挥不充分、发展结构不均衡、投资者获得感不强 等问题。 《行动方案》突出强调，坚持以投资者为本，督促行业机构牢固树立以投资者最佳利益为核心的经营理 念，并贯穿于公司治理、产品发行、投资运作、考核机制等基金运营管理全链条、各环节，恪守"受人 之托、忠人之事"的信义义务，实现从重规模向重投资者回报转型。《行动方案》的这一 ...

Group 1 - The first batch of mutual fund mid-term reports for 2025 has been released, with several fund managers including Ruiyuan Fund, Galaxy Fund, Zhonggeng Fund, and Nanhua Fund disclosing their reports [1] - Ruiyuan Growth Value Mixed Fund, managed by Fu Pengbo, has hidden heavy holdings in stocks such as BQ Materials, Sunny Optical Technology, Guanghui Energy, Innovent Biologics, Alibaba-W, BYD, Dongshan Precision, Bluestar Technology, Su Da Weige, and Berthelot [1] - Galaxy Industrial Power Mixed Fund, managed by Zheng Weishan, maintains a focus on high-end manufacturing industries, with adjustments in industry allocation but still primarily invested in electronics, computers, power equipment, new energy, communications, and machinery [1] Group 2 - The hidden heavy holdings of Galaxy Industrial Power Mixed Fund include stocks like Shunluo Electronics, Zhongke Feimeng, Shengbang Co., Jianghai Co., and Zhichun Technology, with each stock's market value accounting for over 2% of the fund's net asset value as of the end of Q2 [1] - Liu Sheng, manager of Zhonggeng Value Navigation Mixed Fund, expresses optimism about equity assets, highlighting strong business growth attributes in sectors such as pharmaceuticals, new energy, and smart electric vehicles [1] - The innovative drug sector has shown a continuous industrial trend since Q2, although some signs of bubble formation have emerged in trading, yet there are still opportunities to select undervalued companies with improving core competitiveness [1]

Group 1 - Over 300 active equity funds established before 2021 have surpassed their 2021 peak net values since July 2023, indicating positive returns for investors who held since the peak [1][2] - The rebound in active equity funds is attributed to strategic investments in technology, innovative pharmaceuticals, and new consumer sectors by veteran fund managers [1][4] - Notable funds like the Fortune New Vitality Mixed Fund and Huabao Core Advantage Mixed Fund have shown significant recovery, with year-to-date gains of 29.86% and 37.47% respectively, reaching historical highs [2][3] Group 2 - The E Fund Healthcare Industry Mixed Fund has also capitalized on the structural market trends, with its net value surpassing the 2021 peak and reaching a new high of 4.691 yuan [3] - Veteran fund managers such as Fu Pengbo and Chen Peng have made notable comebacks, with their funds achieving substantial gains by focusing on emerging sectors [4] - The importance of adapting investment strategies to current market trends is emphasized, as the era of passive investment is over, requiring active engagement with new industries [5][6]

Group 1 - The core trend observed in the second quarter of 2025 is that many prominent fund managers are increasing their positions in the innovative drug sector, indicating a growing interest in this area [1] - Yongying Fund's Gao Nan reported that the total scale of the funds he manages reached 15.326 billion yuan, a significant increase of nearly 3.5 billion yuan compared to the end of the first quarter [2] - Several funds managed by Gao Nan achieved net value growth exceeding 10%, ranking among the top in their category, showcasing a dual increase in performance and scale [2] Group 2 - The top ten holdings of Gao Nan's flagship fund, Yongying Ruixin, saw significant adjustments, with new additions from the communication equipment sector and innovative drug companies [3] - Major new holdings include companies like ZTE and Innovent Biologics, while positions in BYD and Ninebot were exited [3][4] - The three main investment directions for Gao Nan's funds are communication (TMT), innovative drugs, and light manufacturing, reflecting a clear structural adjustment in response to market themes [4] Group 3 - Gao Nan emphasizes stock selection based on company growth potential and earnings realization, aiming to reduce industry concentration while capturing growth opportunities [5] - The Yongying Technology Driven Fund plans to increase exposure to the artificial intelligence supply chain and reallocate in defense and biomedicine sectors [5] - Gao Nan expresses cautious optimism for the second half of the year, noting improved liquidity conditions and a strong financial risk prevention system established by the government [5] Group 4 - Ruiyuan Fund's Fu Pengbo also significantly increased allocations to the pharmaceutical sector, particularly in innovative drugs, during the second quarter [6] - The Ruiyuan Growth Value Mixed Fund reached a scale of 18.666 billion yuan, with a net value growth rate of 5.80%, outperforming its benchmark by 4.13 percentage points [6][7] - Fu Pengbo's portfolio is heavily weighted towards electronics, internet technology, precision manufacturing, and pharmaceuticals, with a stock position exceeding 92% [7] Group 5 - Fu Pengbo's strategy involves increasing holdings in the pharmaceutical sector, covering innovative drugs and traditional medicine benefiting from AI, while reducing exposure to traditional energy companies [10] - He plans to closely monitor mid-year reports from listed companies and seek industries and companies with rising prosperity [11] - Both Gao Nan and Fu Pengbo share a focus on innovative drugs, providing investors with a reference point for market trends and industry movements [11]

Group 1 - Jianxin Fund plans to invest at least 180 million yuan in its equity public products, having already invested 173 million yuan from Q4 2024 to Q1 2025 [1] - Multiple Hong Kong Stock Connect ETFs have issued warnings about premium risks due to high trading activity during the market closure, with some ETFs experiencing daily turnover rates exceeding 900% [1] - QDII funds have significantly reduced their holdings in US stocks, reallocating to A-shares and Hong Kong stocks [1] Group 2 - Fund manager Ge Lan has reduced her stake in Xinlitai by 2.1673 million shares, as reported in the company's Q1 2025 report [2] - Fund manager Fu Pengbo has slightly increased his position in Furuide by 120,000 shares, according to the latest Q1 2025 report [2] - Fund manager Xiao Nan has increased the allocation to liquor stocks, viewing it as a high-yield bond with domestic demand upside [3] Group 3 - The market showed mixed performance with the Shanghai Composite Index up 0.25% and the Shenzhen Component down 0.36%, with a total trading volume of 1.09 trillion yuan [4] - Hong Kong innovative drug-related ETFs saw strong performance, with some rising by as much as 5.77% [4][5] - A report indicates that the pharmaceutical sector may attract market funds due to previous declines, with investment opportunities focusing on innovative and generic drugs, as well as medical devices and services [7] Group 4 - A new fund, the China Securities Index Free Cash Flow ETF, is set to launch, managed by Xu Rongman, with a performance benchmark based on the China Securities Index Free Cash Flow Index [8]